We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Celera Genomics has gotten out of the drug-development business. The Rockville-based biotechnology company said Wednesday it sold a small-molecule drug program for the treatment of autoimmune diseases to German pharmaceutical giant Schering AG. Washington Business Journal
